Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumours of the Testis

European Urology

Volumn 53, Issue 2, 2008, Pages 260-274

  Heidenreich, Axel ^a   Thüer, David ^a   Polyakov, Sergej ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Research Institute of Oncology and Medical Radiology of the Ministry of Health of the Byelorussian SSR   (Belarus)

Author keywords

Chemotherapy; Mature teratoma; Metastases; Nerve sparing surgery; Nonseminomas; Seminoma; Testis cancer

Indexed keywords

FLUORODEOXYGLUCOSE;

ACUTE KIDNEY FAILURE; ATELECTASIS; CANCER SURVIVAL; CHEMOTHERAPY; CHYLOUS ASCITES; EJACULATION DISORDER; GERM CELL TUMOR; HUMAN; HYPERAMYLASEMIA; INTESTINE OBSTRUCTION; LYMPH NODE DISSECTION; MEDLINE; PARALYTIC ILEUS; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SEMINOMA; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TESTIS TUMOR; TREATMENT INDICATION; TREATMENT OUTCOME; WOUND INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; RETROPERITONEAL SPACE; SEMINOMA; TERATOMA; TESTICULAR NEOPLASMS;

EID: 37349084288     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.10.033     Document Type: Review

References (61)

1. Albers P., Albrecht W., Algaba F., et al. Guidelines on testicular cancer. Eur Urol 48 (2005) 885-894
2. Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 (2004) 1377-1399
3. Beck S.D.W., and Foster R.S. Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer. World J Urol 24 (2006) 267-272
4. Albers P., Weissbach L., Krege S., et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171 (2004) 1835-1838
5. Oldenburg J., Alfsen G.C., Lien H.H., Aas N., Waehre H., and Fossa S.D. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21 (2003) 3310-3317
6. Albers P., Melchior D., and Müller S.C. Surgery in metastatic testicular cancer. Eur Urol 44 (2003) 233-244
7. Gerl A., Clemm C., Schmeller N., Hentrich M., Lamerz R., and Wiliiams W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8 (1997) 41-47
8. Debono D.J., Heilman D.K., Einhorn L.H., and Donohue J.P. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumours. J Clin Oncol 15 (1997) 1455-1464
9. Flechon A., Bompas E., Biron P., and Droz J.P. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 168 (1979) 1975-1979
10. Friedman E.L., Garnick M.B., Stomper P.C., Mauch P.M., Harrington D.P., and Richie J.P. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 3 (1985) 1325-1332
11. Schultz S.M., Einhorn L.H., Conces D.J., Williams S.D., and Loehrer P.J. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin ONcol 7 (1989) 1497-1503
12. Fosså S.D., Borge L., Aass N., Johannessen N.B., Stenwig A.E., and Kaalhus O. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 5 (1987) 1071-1077
13. Ravi R., Rao R.R., and Shanta V. Integrated approach to the management of patients with advanced germ cell tumors of the testis. J Surg Oncol 55 (1994) 47-51
14. Puc H.S., Heelan R., Mazumdar M., et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan Kettering Cancer Center. J Clin Oncol 14 (1996) 454-460
15. Mosharafa A.A., Foster R.S., Leibovich C.C., Bihrle R., Johnson C., and Donohue J.P. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?. J Urol 169 (2003) 2126-2128
16. De Santis M., Becherer A., Bokemeyer C., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update from the multicenter SEMPET trial. J Clin Oncol 22 (2004) 1034-1039
17. Becherer A., De Santis M., Karanikas G., et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 54 (2005) 284-288
18. Kamat M.R., Kulkarni J.N., Tongoankar H.B., and Ravi R. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol 51 (1992) 65-67
19. Hofmockel G., Gruss A., and Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int 57 (1996) 38-42
20. Herr H.W., Sheinfeld J., Puc H.S., et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157 (1997) 860-862
21. Fossa S.D., Ous S., Lien H.H., and Stenwig A.E. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 141 (1989) 557-559
22. Toner G.C., Panicek D.M., Heelan R.T., et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8 (1990) 1683-1694
23. Aprikian A.G., Herr H.W., Bajorin D.F., and Bosl G.J. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 74 (1994) 1329-1334
24. Herr H.W. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?. Br J Urol 80 (1997) 653-657
25. Wood D.P., Herr H.W., Heller G., et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 148 (1992) 1812-1816
26. Rabbani F., Goldenberg S.L., Gleave M.E., Paterson R.F., Murray N., and Sullivan L.D. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of the residual mass sufficient?. Br J Urol 81 (1998) 295-300
27. Albers P., Höltl W., Heidenreich A., and Aharinejad S. Thoracoabdominal resection of retrocrural residual tumors. Akt Urol 35 (2004) 141-150
28. Fujioka T., Nomura K., Okamoto T., Aoki H., Ohhori T., and Kubo T. Retroperitoneal lymph node dissection for testicular tumors using the thoracoabdominal approach. Int Surg 78 (1993) 154-158
29. Skinner D.G., Melamud A., and Lieskovsky G. Complications of thoracoabdominal retroperitoneal lymph node dissection. J Urol 127 (1982) 1107-1110
30. Hartmann J.T., Candelaria M., Kuczyk M.A., Schmoll H.J., and Bokemeyer C. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33 (1997) 843-847
31. Beck S.D., Foster R.S., Bihrle R., Koch M.O., Wahle G.R., and Donohue J.P. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. J Urol 165 (2001) 1517-1520
32. Christmas T.J., Smith G.L., and Kooner R. Vascular interventions during post-chemotherapy retroperitoneal lymph node dissection for metastatic testis cancer. Eur J Surg Oncol (1998) 292-297
33. Beck S.D., and Lalka S.G. Long-term results after inferior vena cava resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg 28 (1998) 808-814
34. Heidenreich A., Derakhshani P., Neubauer S., Krug B., and Engelmann U.H. Evaluation of the inferior vena cava (IVC) by magnetic resonance imaging in advanced testicular germ cell tumors. Eur Urol 33 Suppl 1 (1998) 49 (abstract no. 196)
35. Sonneveld D.J., Sleijfer D.T., Koops H.S., Keemers-Gels M.E., Molenaar W.M., and Hoekstra H.J. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 82 (1998) 1343-1351
36. Hendry W.F., Norman A.R., Dearnaley D.P., et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94 (2002) 1668-1676
37. Qvist H.L., Fossa S.D., Ous S., Hoie J., Stenwig A.E., and Giercksky K.E. Post-chemotherapy tumor residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses?. J Urol 145 (1991) 300-302
38. Beck S.D., Foster R.S., Bihrle R., Donohue J.P., and Einhorn L.H. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?. Cancer 110 (2007) 1235-1240
39. Pfister D., Ohlmann C.H., Thüer D., Sahi D., and Heidenreich A. Post-chemotherapy retroperitoneal resection of residual masses in germ cell cancer with modified template resection. J Urol 177 Suppl (2007) 330 (abstract no. 1000)
40. Witthuhn R., De Geeter P., and Albers P. Retroperitoneal residual tumor resection (RTR) for testicular cancer-template instead of full bilateral resection. J Urol 177 Suppl (2007) 331 (abstract no. 1001)
41. Ehrlich Y., Yossepovitch O., Kedar D., and Baniel J. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection. BJU Int 97 (2006) 1221-1224
42. Eggener S.E., Carver B.S., Loeb S., Kondagunta G.V., Bosl G.J., and Sheinfeld J. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimes for metastatic testicular germ cell tumors. Cancer 109 (2007) 528-535
43. Waples M.J., and Messing E.M. Redo retroperitoneal lymphadenectomy for germ cell tumor. Urology 42 (1993) 1-4
44. Cespedes R.D., and Peretsman S.J. Retroperitoneal recurrences after retroperitoneal lymph node dissection for low-stage nonseminomatous germ cell tumors. Urology 54 (1999) 548-552
45. Sexton W.J., Wood C.G., Kim R., and Pisters L.L. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol 169 (2003) 1353-1356
46. McKiernan J.M., Motzer R.J., Bajorin D.F., Bacik J., Bosl G.J., and Sheinfeld J. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence and outcome. Urology 62 (2003) 732-736
47. Heidenreich A., Ohlmann C., Hegele A., and Beyer J. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol 47 (2005) 64-71
48. Albers P., Ganz A., Hannig E., Miersch W.D., and Müller S.C. Salvage surgery of chemorefractory germ cell tumors with elevated markers. J Urol 164 (2000) 381-384
49. Beck S.D., Foster R.S., Bihrle R., Einhorn L.H., and Donohue J.P. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 23 (2005) 6149-6156
50. Nash P.A., Leibovitch I., Foster R.S., Bihrle R., Rowland R.G., and Donohue J.P. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J Urol 159 (1998) 707-710
51. Stephenson A.J., Tal R., and Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol 176 (2006) 1996-1999
52. Heidenreich A., Seger M., Schrader A.J., Hofmann R., Engelmann U.H., and Beyer J. Surgical considerations in residual tumor resection following inductive chemotherapy for advanced testicular cancer. Eur Urol Suppl 3 2 (2004) 161 (abstract no. 632)
53. Heidenreich A., Albers P., Hartmann M., et al. Complications of primary nerve-sparing lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169 (2003) 1710-1714
54. Mosharafa A.A., Foster R.S., Koch M.O., Bihrle R., and Donohue J.P. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 171 (2004) 1839-1841
55. Leibovitch I., Mor Y., Golomb J., and Ramon J. The diagnosis and management of postoperative chylous ascites. J Urol 167 (2002) 449-457
56. Vergouwe Y., Steyerberg E.W., Foster R.S., Habbema J.D.F., and Donohue J.P. Validation of a prediction model and its predictors for the histology of residual masses in nonseminonatous testicular cancer. J Urol 165 (2001) 84-88
57. Vergouwe Y., Steyerberg E.W., de Wit R., et al. External validation of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer 88 (2003) 843-847
58. Vergouwe Y., Steyerberg E.W., Foster R.S., et al. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicenter validation with more than 1000 patients. Eur Urol 51 (2007) 424-432
59. Heidenreich A. Residual tumor resection following inductive chemotherapy in advanced testicular cancer. Eur Urol 51 (2007) 299-301
60. Pfister D., Seger M., Schrader A.J., Ohlmann C.H., and Heidenreich A. Prediction of residual retroperitoneal mass histology following post-chemotherapy retroperitoneal surgery for metastatic nonseminomatous germ cell tumors: role of mdr-1 and mismatch repair genes. J Urol 177 Suppl (2007) 197 (abstract no. 588)
61. Fizazi K., Tjulandin S., Salvioni R., et al. Viable malignant cells after primary chemotherapy for disseminated nonseminatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy results from an international study. J Clin Oncol 19 (2001) 2647-2657